BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
BBIO POWR Grades
- Growth is the dimension where BBIO ranks best; there it ranks ahead of 63.73% of US stocks.
- BBIO's strongest trending metric is Quality; it's been moving down over the last 179 days.
- BBIO ranks lowest in Stability; there it ranks in the 3rd percentile.
BBIO Stock Summary
- BRIDGEBIO PHARMA INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.57% of US listed stocks.
- BBIO's price/sales ratio is 25.03; that's higher than the P/S ratio of 94.92% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -0.68 for BRIDGEBIO PHARMA INC; that's greater than it is for only 5.55% of US stocks.
- If you're looking for stocks that are quantitatively similar to BRIDGEBIO PHARMA INC, a group of peers worth examining would be STRO, EXAI, CEVA, BPMC, and DTIL.
- BBIO's SEC filings can be seen here. And to visit BRIDGEBIO PHARMA INC's official web site, go to bridgebio.com.
BBIO Valuation Summary
- BBIO's price/sales ratio is 26.4; this is 1289.47% higher than that of the median Healthcare stock.
- BBIO's EV/EBIT ratio has moved up 8.7 over the prior 45 months.
Below are key valuation metrics over time for BBIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BBIO | 2023-03-17 | 26.4 | -1.6 | -4.3 | -8.4 |
| BBIO | 2023-03-16 | 26.9 | -1.7 | -4.3 | -8.5 |
| BBIO | 2023-03-15 | 27.8 | -1.7 | -4.5 | -8.6 |
| BBIO | 2023-03-14 | 28.4 | -1.8 | -4.6 | -8.8 |
| BBIO | 2023-03-13 | 28.3 | -1.8 | -4.6 | -8.8 |
| BBIO | 2023-03-10 | 27.4 | -1.7 | -4.4 | -8.6 |
BBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BBIO has a Quality Grade of D, ranking ahead of 17.97% of graded US stocks.
- BBIO's asset turnover comes in at 0.068 -- ranking 297th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BBIO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.068 | 0.998 | -0.332 |
| 2021-03-31 | 0.010 | 1.000 | -0.451 |
| 2020-12-31 | 0.010 | 1.000 | -0.555 |
| 2020-09-30 | 0.026 | 1.000 | -0.593 |
| 2020-06-30 | 0.051 | 0.938 | -0.669 |
| 2020-03-31 | 0.063 | 0.938 | -0.909 |
BBIO Price Target
For more insight on analysts targets of BBIO, see our BBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $80.40 | Average Broker Recommendation | 1.28 (Strong Buy) |
BBIO Stock Price Chart Interactive Chart >
BBIO Price/Volume Stats
| Current price | $14.90 | 52-week high | $19.94 |
| Prev. close | $13.58 | 52-week low | $4.98 |
| Day low | $11.75 | Volume | 9,502,000 |
| Day high | $14.90 | Avg. volume | 2,946,012 |
| 50-day MA | $11.78 | Dividend yield | N/A |
| 200-day MA | $10.18 | Market Cap | 2.26B |
BridgeBio Pharma, Inc. (BBIO) Company Bio
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Latest BBIO News From Around the Web
Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mutations – If successful, the combination of investigational therapy BBP-398 and OPDIVO has the potential to address the serious unmet need for patients with KRAS-mutated non-small cell lung cancer (NSCLC) and o |
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's WhyShares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism. |
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I patients - BridgeBio also shared 15-month results from its ongoing Phase 2 study, which showed a doubling of glycosylated ⍺DG in LGMD2I patients treated with BBP-418 - A sustained decrease of ≥70% in creatine kinase (CK), a marker of muscle breakdown, was observed with BBP-418 treatment at 15 month |
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an oral presentation and posters at the Muscular Dystrophy Association (MDA) 2023 Annual Meeting - Additionally, BridgeBio will host an investor call with Jeffrey Rosenfeld, M.D., Ph.D., a specialist in neuromuscular medici |
Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year. |
BBIO Price Returns
| 1-mo | 27.90% |
| 3-mo | N/A |
| 6-mo | 50.05% |
| 1-year | 43.82% |
| 3-year | 63.20% |
| 5-year | N/A |
| YTD | 95.54% |
| 2022 | -54.32% |
| 2021 | -29.63% |
| 2020 | 102.88% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...